Fig. 4From: Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell linesPredicted sensitivity based on mutation status. Violin plots of predicted ln (IC50) values of trametinib based on RNA-seq gene expression data from TCGA tumor samples for those with and without mutations in BRAF a, KRAS b and NRAS c. * p < 0.05; ** p < 0.005; **** p < 10− 6. Wilcoxon rank-sum test, two-sidedBack to article page